Sort   by:  
 Page size 
Models,MultiomicsSKBR3 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2703 | Cell Collective
Models,MultiomicsBT474 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2697 | Cell Collective
Models,MultiomicsHCC1954 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2698 | Cell Collective
Models,MultiomicsBT474 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2699 | Cell Collective
Models,MultiomicsHCC1954 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2700 | Cell Collective
Models,MultiomicsSKBR3 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2701 | Cell Collective
ModelsMammalian Cell Cycle
BACKGROUND: In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to t...
1607 | Cell Collective
Sort   by:  
 Page size